FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Top Story

Biogen ups the ante for Facet

Biogen Idec has made its "best-and-final offer" for Facet Biotech. The big biotech has upped its bid to $17.50 per share (around $430 million), up from the $14.50 per share--or $356 million--Biogen extended in September. Report

CEO Pay

Biotech CEO salaries up, but bonuses down

Life science CEOs made an average base salary of $273,000, up 3.2 percent from 2008 levels. That's according to the 10th annual Compensation and Entrepreneurship study, released by J. Robert Scott and Ernst & Young. Report ⇒

Special Report

The 2009 Biotech Graveyard

Biotech GraveyardIn the spirit of Halloween FierceBiotech brings you the 2009 Biotech Graveyard; a list of 16 unfortunate companies that didn't have the money, expertise or programs to survive the economic crisis. Report ⇒

Profile

Emerging Drug Developer: Flexion Therapeutics

Mike Clayman and Neil Bodick are no strangers to the development process. Together they founded Chorus, Eli Lilly's in-house, early-stage development group, which was charged with finding the shortest path possible to proof-of-concept data. And they've garnered $33 million from a Series A to finance their own start-up development outfit, bringing all the skills they've learned along the way to advance therapies taken off the shelves of Big Pharma's R&D operations. Profile